TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06929806: Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure

Sponsor: Pharmacosmos A/S · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 1900 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT06929806 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06929806 Rescue Dossier →